| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 146.24B | 147.57B | 142.99B | 143.04B | 115.58B | 103.25B |
| Gross Profit | 30.38B | 30.68B | 28.01B | 30.14B | 26.15B | 25.18B |
| EBITDA | 10.96B | 14.35B | 14.87B | 15.55B | 13.59B | 15.38B |
| Net Income | 4.49B | 5.96B | 6.17B | 8.59B | 5.89B | 7.12B |
Balance Sheet | ||||||
| Total Assets | 141.32B | 141.53B | 136.31B | 126.65B | 121.27B | 107.83B |
| Cash, Cash Equivalents and Short-Term Investments | 18.93B | 16.86B | 21.66B | 23.55B | 29.25B | 25.66B |
| Total Debt | 22.29B | 18.86B | 11.57B | 12.62B | 14.55B | 14.09B |
| Total Liabilities | 47.05B | 47.22B | 41.25B | 39.99B | 39.37B | 32.34B |
| Stockholders Equity | 94.26B | 94.31B | 95.05B | 86.66B | 78.73B | 72.79B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -5.98B | 2.04B | -128.00M | 5.39B | 13.18B |
| Operating Cash Flow | 0.00 | 13.68B | 12.01B | 6.70B | 9.02B | 16.25B |
| Investing Cash Flow | 0.00 | -20.91B | -10.37B | -5.94B | -4.32B | -2.23B |
| Financing Cash Flow | 0.00 | 3.19B | -5.77B | -8.30B | -2.99B | -3.26B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ¥64.28B | 13.15 | ― | 3.33% | 3.03% | 28.27% | |
77 Outperform | ¥84.40B | 16.84 | 10.57% | 1.82% | 15.12% | 40.72% | |
76 Outperform | ¥70.48B | 5.97 | ― | 3.14% | 3.55% | 214.69% | |
75 Outperform | ¥65.88B | 14.08 | ― | 4.18% | 0.32% | -43.10% | |
74 Outperform | ¥105.60B | 7.58 | ― | 4.71% | 1.16% | 167.89% | |
69 Neutral | ¥97.82B | 17.14 | ― | 1.21% | 71.39% | 87.22% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
Sumitomo Seika Chemicals reported a decline in its financial performance for the three months ending June 30, 2025, with net sales decreasing by 3.6% and significant drops in operating and ordinary profits. This downturn reflects challenges in the market, impacting the company’s profitability and signaling potential concerns for stakeholders.